Human ICOS-expressing Raji Cells

Product Unit size Cat. code Docs. Qty. Price

Raji-hICOS Cells

Human lymphoblast cells - ADCC ICOS Target Cells

Show product

3-7 x 10e6 cells


Human ICOS-expressing B cells

Raji-hICOS cells were developed from the human Raji cell line, a human B lymphocyte-derived cell line, and engineered to stably overexpress the human ICOS gene. Raji cells have been successfully used as target cells in human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells.

Inducible Co-stimulator (ICOS, CD278) is a  co-stimulatory immune checkpoint (IC) and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in  CD4+ and CD8+ T cells upon their activation, whereas its ligand ICOSL (also known as CD275), is mostly expressed on antigen-presenting cells [1]. The interaction between ICOS and ICOSL delivers a secondary co-stimulatory signal through the activation of the transcription factor AKT, which promotes T cell proliferation and differentiation as well as the production of cytokines  [1]. In tumor immunity, ICOS is involved in the amplification of the anti-tumor cytotoxic CD8+ T cell response, as well as the 'pro-tumor' function and maintenance of regulatory T cells (Tregs). Therefore, both agonistic and antagonistic monoclonal antibodies (mAbs) targeting this pathway are being investigated in combinational cancer immunotherapy [2]. Notably, ICOS agonistic mAbs have been shown to potentiate the effects of anti-CTLA-4 mAbs [3]. 

Features of Raji-hICOS cells:

Surface expressed markers and ICs in Raji-hICOS cells
Surface expressed markers and ICs in Raji-hICOS cells

  • Stable overexpression of the human ICOS gene 
  • Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
  • Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL

Applications for Raji-hICOS cells:

  • Target cell line for ADCC assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells
  • Target cell line for cell toxicity assays using NK or CAR-T cells
  • For use in the development of novel human ICOS agonistic and antagonistic mAbs 

Validation of Raji-hICOS cells:

  • Overexpression of ICOS verified by flow cytometry
  • Functionally tested as target cells in ADCC assays using anti-human ICOS mAbs and Jurkat-Lucia™ NFAT-CD16 cells
  • Guaranteed mycoplasma-free



1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.
2. Solinas, C. et al. 2020. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open 5.
3. Soldevilla, M.M. et al. 2019. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Mol Ther 27, 1878-1891.


Validation of the expression of human ICOS by Raji-hICOS cells by flow cytometry
Validation of the expression of human ICOS by Raji-hICOS cells by flow cytometry

Validation of the expression of human ICOS by Raji-hICOS cells. Raji-Null (A) and Raji‑hICOS (B) cells were incubated with a PE-conjugated Anti-hICOS mAb for 30 minutes. The binding affinity was then measured using flow cytometry.

ADCC assay using various anti-human ICOS antibody isotypes and Raji-hICOS target cells
ADCC assay using various anti-human ICOS antibody isotypes and Raji-hICOS target cells

Comparison of ADCC potency for native and engineered anti-human ICOS antibody isotypes. Raji-hICOS cells were incubated with gradient concentrations of Anti-hICOS or Anti-β-galactosidase (β-Gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Back to the top


Antibiotic resistance: Blasticidin

Growth medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS; 30 min at 56 °C), Pen-Strep (100 U/ml-100 µg/ml), 100 µg/ml Normocin™

Test medium: IMDM, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated FBS, Pen-Strep (100 U/ml-100 µg/ml)

Quality control:

  • Human ICOS expression has been verified by flow-cytometry.
  • Induction of antibody-dependent cellular cytotoxicity (ADCC) has been validated using anti-hICOS antibodies and InvivoGen's Jurkat-NFAT Lucia™ CD16 reporter cell line.
  • The stability for 20 passages following thawing has been verified.
  • Raji-hICOS cells are guaranteed mycoplasma-free.

These products are covered by a Limited Use License (See Terms and Conditions).

Back to the top


  • 3-7 x 106 Raji-hICOS cells in a cryovial or shipping flask.
  • 1 ml of Blasticidin (10 mg/ml). Store at 4 °C or at -20 °C.
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi. Store at -20 °C.

IMPORTANT: If cells are shipped frozen (i.e. in a cryovial) and are not frozen upon arrival, contact InvivoGen immediately.

Shipped on dry ice Shipped on dry ice (Europe, USA & Canada)

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty